Bitcoin News: Saylor “Sell a Kidney” Call is Now a BTC Exit?

Strategy is making huge news as it abandons its never-sell Bitcoin policy, putting 818,334 BTC, or nearly 4% of total supply, in play as an actively managed treasury asset. CEO Phong Le confirmed on Tuesday’s earnings call that the company will now consider selling BTC to buy dollars or retire debt, provided the trade is accretive to bitcoin per share. A direct reversal of the philosophy Michael Saylor built the entire Strategy brand around.

The position was acquired for $61.81 billion at an average cost of $75,500 per coin. A $12.5 billion net loss in Q1 2026, driven by the BTC price decline at the start of the year, provided the financial pressure that forced the pivot. MSTR shares jumped 3% in after-hours trading on the announcement.

Will Strategy dump its entire stack? It almost certainly will not. But thinking of selling when people were asked to sell their kidneys is not a good look.

Discover: Bitcoin price analysis – key support levels and what breaks them

What Happens to Bitcoin If Strategy Starts Selling?

Strategy’s 818,334 BTC is worth $61.8 billion at the average acquisition cost, but at the current spot value of $81,500, the position is valued at $66.8 billion. The number is way too big for a single order book to absorb cleanly.

Strategy’s purchases of $500 million–$1 billion in BTC have reliably moved spot prices upward by 2%–4% in the sessions following disclosure. The reverse dynamic of a coordinated sell program would face thinner liquidity on the ask side, particularly below the $75,000–$78,000 support band, where institutional bids concentrate.

Any meaningful disposal would almost certainly route through OTC desks and not exchange order books. That limits slippage but does not eliminate price impact. A block sale of 5,000–10,000 BTC would represent one of the largest single institutional transactions in recent cycle history and would carry significant signal weight regardless of execution venue.

Le’s stated condition of selling only when it is accretive to bitcoin per share creates a governor on the program. But the market liquidity at the $70,000–$74,000 band is thin. If BTC breaks below the company’s average cost basis, the calculus around debt servicing versus hodling shifts materially.

Forget the News, You Can Buy Bitcoin Hyper and Still Keep Your Kidney

Strategy’s current news is scary for retail Bitcoin holders. People are looking for an asymmetrical upside when BTC is stuck under $100K, something that has Bitcoin security, built to fix Bitcoin flaws, and doesn’t require selling a kidney to buy.

Bitcoin Hyper ($HYPER) is a project drawing attention. Positioned as the first-ever Bitcoin Layer 2 with Solana Virtual Machine (SVM) integration, it aims to address Bitcoin’s three core limitations simultaneously: slow transactions, high fees, and limited programmability.

In short, Hyper is delivering sub-second finality and low-cost smart contract execution while inheriting Bitcoin’s security model.

The presale has raised more than $32.5 million at a current token price of $0.0136, with 36% APY staking available for early participants. It’s still cheap, and at that raised level, meaningful institutional and retail appetite is already present, but the price remains early-stage by any measure. Keep your kidneys and get Hyper.

Research Bitcoin Hyper before the presale concludes.

The post Bitcoin News: Saylor “Sell a Kidney” Call is Now a BTC Exit? appeared first on Cryptonews.